Burkina Faso
Tuberculosis profile
| High HIV burden |
Population  2012 16 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (0.6–2.5) 8.5 (3.7–15)
Mortality (HIV+TB only) 0.47 (0.4–0.54) 2.9 (2.5–3.3)
Prevalence  (includes HIV+TB) 14 (6.9–22) 82 (42–136)
Incidence  (includes HIV+TB) 9 (7.6–10) 54 (46–63)
Incidence (HIV+TB only) 1.6 (1.3–1.8) 9.5 (8–11)
Case detection, all forms (%) 58 (50–69)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 583 (71) Relapse 194 (50)
Smear-negative 662 (13) Treatment after failure 157 (40)
Smear-unknown / not done 0 (0) Treatment after default 38 (10)
Extrapulmonary 617 (12) Other 0 (0)
Other 154 (3)      
Total new 5 016   Total retreatment 389  
           
Other (history unknown) 0        
Total new and relapse 5 210   Total cases notified 5 405  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.5    
Age < 15 52 73 51
Laboratories 2012
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 78   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 74  
Retreatment 75  
TB/HIV 2012 Number (%)
TB patients with known HIV status 4 567 (84)
HIV-positive TB patients 671 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 647 (96)
HIV-positive TB patients on antiretroviral therapy (ART) 503 (75)
HIV-positive people screened for TB 7 357  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
79 (4–150) 75 (29–120)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 7 (<1%) 72 (19%) 84
Laboratory-confirmed MDR-TB cases 3 34 38
Patients started on MDR-TB treatment     26
Financing TB control 2013
National TB programme budget (US$ millions) 1.7
% Funded domestically 5%
% Funded internationally 95%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data